1.Competitive price
2.Fast Delivery Within 2 days
3.SGS , BV, GMP,ISO approve
4.Professional factory
$1.00 - $100.00 / Kilogram
Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor, which is the main receptor responsible for ADP-induced platelet aggregation.
Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world’s first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.
It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.
| Test Items | Specification | Results |
| Description | White to off white crystalline powder | Comply |
| Melting point | 166-170°C | 167.3-168.1°C |
| Identification | Positive reaction | Positive reaction |
| Related substances | ≤1.0% | 0.16% |
| Loss on drying | ≤0.5% | 0.06% |
| Residue on ignition | ≤0.1% | 0.02% |
| Chloride | ≤0.014% | <0.014 |
| Heavy Metals | ≤20ppm | <20ppm |
| Clarity of solution | Conform to standard | Complies |
| Microbial Limit | ≤20ppm | <20ppm |
| Assay | ≥99.0% | 99.12% |
Ticagrelor, a new platelet aggregation inhibitor successfully developed by AstraZeneca (U.S.), is the world’s first reversible combination orally-administered P2Y12 adenosine diphosphate receptor antagonist.
It is used to reduce cardiovascular death and heart attacks in patients with acute coronary syndrome (ACS.) Rapid onset after oral administration, and can effectively improve symptoms of patients with ACS. Thienopyridines is a reversible P2Y12 inhibitor, so it is particularly applicable towards patients who need to undergo anticoagulant therapy before surgery.
